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Original Article
Ethanol sclerotherapy or polidocanol
sclerotherapy for symptomatic hepatic cysts
Titus FM Wijnands*1, Bastian Schoenemeier2,*, Andrej Potthoff2,
Tom JG Gevers1, Hans Groenewoud3, Michael J Gebel2, Kinan Rifai2,
Michael P Manns2 and Joost PH Drenth1
Abstract
Background: Over the past decades, multiple approaches to aspiration sclerotherapy of large symptomatic hepatic cysts have
been investigated. However, comparative data are scarce.
Objective: The objective of this article is to compare cyst reduction, symptomatic relief, and adverse events between ethanol
sclerotherapy and polidocanol sclerotherapy.
Methods: This retrospective study included adults having a symptomatic hepatic cyst treated at a European tertiary referral
center with ethanol sclerotherapy (Center 1) or polidocanol-sclerotherapy (Center 2). We compared cyst diameter reduction
(%) and symptom improvement (yes/no) within 12 months’ post-treatment between centers using multivariate regression
analyses adjusted for confounding factors. Finally, we compared adverse events using Fisher’s exact test.
Results: We included 71 patients from Center 1 and 66 patients from Center 2 (median age 57 years; 126/137 (92%) female).
Cyst reduction was comparable between Centers 1 and 2: 37.5% (IQR 15.7–61.0%) versus 44.2% (IQR 24.6–60.5%), respect-
ively (p¼ 0.35). Correspondingly, symptomatic relief was comparable: 30/53 (56.6%) versus 43/66 (65.2%), respectively
(p¼ 0.88). Center 1 reported significantly more (11 versus 3; p¼ 0.047) adverse events than Center 2.
Conclusion: We found comparable cyst reduction and symptomatic relief rates between ethanol- and polidocanol sclero-
therapy, while adverse events occurred more often in the ethanol group. Prospective studies focused on clinical response are
needed to further explore differences between approaches.
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Key summary
Established knowledge
1. Aspiration sclerotherapy is an eﬀective and safe method to reduce hepatic cysts.
2. Although multiple diﬀerent treatment approaches have been published in the last decades, formal com-
parisons are scarce.
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Significant and/or new findings
1. In this non-randomized study, hepatic cyst reduction and symptomatic relief rates after ethanol- or
polidocanol-sclerotherapy approaches seemed highly comparable.
2. Although numbers were small, we found more adverse events after ethanol-sclerotherapy compared to
polidocanol-sclerotherapy.
Introduction
Hepatic cysts are ﬂuid-ﬁlled cavities located in the liver
that arise from congenital malformations of the biliary
tract. Prevalence is estimated around 2.5% to 18.0% of
the general population.1–3 Hepatic cysts can occur as
solitary or multiple lesions in the context of polycystic
liver disease (PLD).4 Although typically asymptomatic,
a proportion of patients with large hepatic cysts may
develop symptomatic disease. Treatment should be
considered in these cases and encompasses surgical or
radiological interventions.5
Aspiration sclerotherapy consists of ultrasonog-
raphy (US) guided puncture and drainage of the hep-
atic cyst with subsequent instillation of a sclerosing
agent aiming to eradicate the lining cystic epithelium.
Lysis of these ﬂuid-producing cells results in regression
of the cyst.
Multiple protocols for aspiration sclerotherapy are
available with a number of variables that diﬀer between
approaches. Examples of these variables are the type of
sclerosing agent (e.g. ethanol, tetracycline, and polido-
canol), the injected volume of the sclerosing agent, and
instillation time.6–12 The literature mainly contains case
series that highlight one speciﬁc protocol. However, few
have compared the results between diﬀerent approaches.
For this study, we compared two institutes that were
subjected to a distinct aspiration sclerotherapy protocol
including the use of diﬀerent sclerosing agents: ethanol
and polidocanol. Historically, ethanol has been gener-
ally applied as a sclerosing agent in most centers.13
However, because of side eﬀects of pain and intoxica-
tions, other sclerosing agents has been explored in
recent decades. One of these alternative agents is poli-
docanol. Inspired by the success rates in varices and
renal cysts, polidocanol was injected into hepatic cysts
with both toxic and anesthetic eﬀects on the epithe-
lium.14,15 Our aim was to compare eﬃcacy in terms of
cyst reduction, clinical response, and safety between
these diﬀerent standardized aspiration sclerotherapy
approaches.
Materials and methods
Study design and population
In this study we evaluated treatment outcome after
aspiration sclerotherapy of hepatic cysts. This
retrospective cohort consists of patients who were trea-
ted in the following two tertiary referral centers: (a)
Radboud University Medical Center, Nijmegen, the
Netherlands, and (b) the Medical School of
Hannover, Hannover, Germany. Ethics approval was
obtained by the local medical ethics committee of both
centers. As this was an observational, retrospective
cohort, informed consent was not deemed necessary
by the ethics boards.
We included adult (18 years) patients who under-
went aspiration sclerotherapy of a symptomatic, non-
parasitic, non-neoplastic hepatic cyst between 2004 and
2012 (Center 1) and 2007 and 2013 (Center 2).
Indication for aspiration sclerotherapy was based on
the presence of symptoms (e.g. abdominal distension,
pain, dyspnea, and early satiety) that were likely to
result from compression by a large hepatic cyst. Both
centers treated solitary cysts and dominant cysts within
the context of PLD. A dominant cyst was identiﬁed as
the largest hepatic cyst surrounded by smaller cysts.
The treated cyst had to be measured by US or com-
puted tomography (CT) within six months before and
within 12 months after aspiration sclerotherapy.
We excluded a patient if the treated cyst could not be
identiﬁed from other (nontreated) cysts on postinter-
ventional imaging. Measurements that were recorded
after a second intervention of the cyst (i.e. second aspir-
ation sclerotherapy or surgical fenestration) were not
included.
Aspiration sclerotherapy procedures
and follow-up
Both centers worked with standardized, single-session
procedures. Center 1 performed US-guided drainage of
the cyst using a 5-French pigtail catheter (Cook
Medical, Bloomington, IN, USA).16 Subsequently,
100% ethanol was injected into the cyst with a
volume of 10% of the aspirated cyst ﬂuid volume.
For safety reasons a maximal amount of 50ml was
instilled. Patients did not change position during the
procedure. After 10 minutes, ethanol was re-aspirated
from the cyst cavity. To prevent ethanol leakage,
the catheter was withdrawn while applying suction.
The procedure was performed using conscious sedation
and local anesthesia. In Center 2, cysts were aspirated
under US guidance (20G Chiba needle), followed by
instillation of polidocanol 1% (Aetoxisclerol 1%,
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Kreussler Pharma, Wiesbaden, Germany) in a volume
of 10% of aspirated volume with a safety margin of
120ml. After ﬁve minutes polidocanol was partially
re-aspirated and a maximum of 60ml polidocanol
remained in the cyst.17 In Center 2, only local anesthe-
sia was applied.
In both centers, patients visited the outpatient clinic
before (<6 months) and after (<12 months) aspiration
sclerotherapy. During these visits, US was performed to
assess the three orthogonal cyst diameters from which
one mean diameter was calculated (Figure 1). In add-
ition, during both visits, patient symptoms of were moni-
tored. Treatment protocols remained unchanged during
the study period.
Study endpoints
The primary endpoint of this study was proportional
(%) cyst diameter reduction compared between treat-
ment strategies of Centers 1 and 2. To calculate pro-
portional diameter reduction, we used the baseline and
last available measurement within 12 months after
aspiration sclerotherapy. Secondary endpoints were
symptomatic change and safety. Symptomatic change
was extracted from the medical charts and dichoto-
mized into two categories: reduction or no reduction of
symptoms. To evaluate safety, we documented type,
rate, and date of any complication following treatment
within 12 months.
Data collection
We performed an Electronic Patients Database search
and included all patients who underwent aspiration
sclerotherapy between January 2004 to December
2012 (Center 1) and January 2007 to December 2013
(Center 2). Data were subtracted from medical charts.
Patient history and US or CT images were used to
assess patient eligibility. We assembled a dataset with
all endpoints. In addition, we included the following
variables: age, gender, PLD (> 20 hepatic cysts, yes/
no), relevant medical history, and dates of aspiration
sclerotherapy and follow-up. Data were entered into a
pooled database by one of the two primary researchers
and cross-checked for errors.
Statistical analysis
Frequency tables were provided for all demographic
information and compared between centers.
Continuous and categorical data were compared
between centers using the Mann–Whitney U test and
Pearson’s Chi-square test, respectively. By linear regres-
sion analysis, we compared proportional cyst diameter
reduction between centers. We included proportional
diameter reduction as a dependent variable and center
as an independent variable. Moreover, we included the
following variables to correct for confounding: age,
gender, PLD, baseline cyst diameter, amount of
Figure 1. Orthogonal measurement of a treated hepatic cyst.
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sclerosing agent, and follow-up time. Similarly, we
compared symptomatic change (dependent variable)
between centers (independent variable) using logistic
regression analysis including the aforementioned con-
founding variables.
Within each treatment regimen, we compared cyst
reduction between patients with or without symptom-
atic relief using the Mann–Whitney U test. In addition,
we compared cyst reduction and symptomatic relief
between patients with or without PLD, by the Mann–
Whitney U and Chi-square test, respectively. Finally,
adverse event rates were compared using Fisher’s
exact test. We performed statistical analysis using
IBM SPSS statistics (SPSS Inc, Chicago, IL, USA).
All reported p values were two tailed, and values< 0.05
were considered statistically signiﬁcant.
Results
Baseline characteristics
We identiﬁed 111 patients in Center 1 and 121 patients
in Center 2 (Figure 2). From these 232 patients, 137
were eligible for inclusion: 71 from Center 1 and 66
patients from Center 2. Absence of baseline (n¼ 12)
or follow-up (n¼ 32) imaging or insuﬃcient documen-
tation (n¼ 19) were main reasons for exclusion. All
treated cysts could be identiﬁed after treatment. Re-
intervention rates were comparable between centers
(Figure 2). Age, gender, underlying diagnosis and
location of the cyst were comparable between centers
(Table 1). The occurrence of renal cysts (21.1% versus
51.5%; p< 0.01) and baseline cyst diameter (11.2 cm
(interquartile range (IQR) 8.4–16.0 cm) versus 8.4 cm
(IQR 7.0–10.7 cm); p< 0.01) diﬀered between centers.
Cyst reduction
In Center 1, cysts reduced to a mean diameter of 6.7 cm
(IQR 3.7–10.6 cm) after a follow-up of two months
(IQR 1–5 months), corresponding with a reduction of
37.5% (IQR 15.7–61.0%). Patients treated in Center 2
had a median diameter of 4.9 cm (3.5–6.8 cm) after
seven months (IQR 3–9 months), which was a propor-
tional reduction of 44.2% (IQR 24.6–60.5 months)
(Figure 3). By multivariable linear regression analysis
we found no statistically signiﬁcant diﬀerence between
centers (p¼ 0.35). Although median follow-up time dif-
fered between centers, this was not associated with a
diﬀerence in cyst reduction between centers (p¼ 0.87).
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Figure 2. Flowchart: identification and selection of patients in
Centers 1 and 2.
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Figure 3. Cyst diameter reduction compared between Centers 1
and 2.
aMultivariate regression analysis.
Table 1. Demographics.
Center 1
(n¼ 71)
Center 2
(n¼ 66) p valuea
Age at treatment, years 55 (47–65) 58 (52–67) 0.16
Gender, female (%) 68 (95.8) 58 (87.9) 0.09
Diagnosis, PLD (%) 56 (78.9) 50 (75.8) 0.67
Renal cysts, yes (%) 15 (21.1) 34 (51.5) <0.01
Baseline cyst diameter, cm 11.2 (8.4–16.0) 8.4 (7.0–10.7) <0.01
Liver lobe, rightb 39 (54.9) 38 (57.6) 0.76
aContinuous values by Mann–Whitney U test; categorical data by Pearson
Chi-Square test.
bIn both centers, five patients had a centrally located cyst.
PLD: polycystic liver disease (>20 hepatic cysts).
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Symptomatic relief
In Center 1, 30 out of 53 (56.6%) patients reported
symptomatic relief, compared to 43 out of 66
(65.2%) in Center 2. In Center 1, clinical response
could not be retrieved from the medical charts for
18 patients. Logistic regression showed no diﬀerences
between centers (odds ratio (OR) 0.90; 95% conﬁdence
interval (CI) 0.23–3.52; p¼ 0.88). Again, median
follow-up time was not associated with diﬀerences in
symptom response (OR 1.02; 95% CI 0.85–1.20;
p¼ 0.90).
Cyst reduction and symptomatic relief
In both centers, higher eﬃcacy of cyst reduction was
associated with improved clinical response. In Center 1,
we found signiﬁcantly larger median cyst reduction
in patients who reported a decrease in symptoms
compared to patients without symptom improvement:
48.8% (32.0–65.3%) versus 23.4% (10.3–61.0%),
respectively (p¼ 0.02). In Center 2, we found simi-
lar results: 53.2% (32.5–68.7%) versus 28.7%
(7.9–47.0%), respectively (p¼ 0.03).
Cyst reduction and symptomatic relief compared
between diagnosis
In general, we observed higher cyst and symptom
reduction rates in patients without PLD.
In Center 1, non-PLD and PLD patients had com-
parable cyst reduction rates: 42.7% (15.2–86.7%)
versus 34.8% (16.1–55.1%); p¼ 0.38. In contrast, in
Center 2, cysts of patients without PLD had stronger
regression rates: 70.3% (55.0–84.6%) versus 36.3%
(20.9–53.4%); p< 0.01.
Correspondingly, symptom reduction was higher in
patients without PLD compared to PLD patients in
both centers: 7/10 (70.0%) versus 23/43 (53.5%;
p¼ 0.34) in Center 1, and 16/16 (100%) versus 27/54
(54.0%; p< 0.01) in Center 2.
Safety
In total, Center 1 reported 11 adverse events: Five
patients had pain following treatment, ﬁve patients
had a suspected cyst hemorrhage, and one patient
developed a hepatic cyst infection (Table 2). No etha-
nol-intoxications were reported. In Center 2, three
adverse events were reported: one hepatic cyst hemor-
rhage and two cyst infections; no patients reported
pain. Center 1 reported signiﬁcantly more adverse
events (p¼ 0.047). All adverse events were treated con-
servatively (analgesics or antimicrobial treatment) and
resolved without sequelae.
Discussion
The primary ﬁnding of this study is that we found com-
parable eﬃcacy rates of cyst reduction and clinical relief
between two diﬀerent aspiration sclerotherapy
approaches. In contrast, ethanol sclerotherapy resulted
in more adverse events compared to polidocanol
sclerotherapy.
In the past decades, multiple centers have described
their experience with sclerotherapy protocols.13 More
recently, studies compared single variables within
these protocols.18,19 Nonetheless, head-to-head com-
parisons between these strategies are scarce. In this
study, we compared two distinct treatment protocols
using diﬀerent sclerosing agents, volumes and time
intervals. Despite these two diﬀerent approaches, we
found highly comparable cyst reduction, re-interven-
tion, and symptomatic relief rates.
Compared to previous studies, we found lower cyst
diameter reduction and clinical response rates.20,21
These smaller reduction rates may be explained by
our short follow-up interval. Previous studies reported
continuous cyst reduction in the ﬁrst year after aspir-
ation sclerotherapy.22 As cyst reduction continues over
time, our follow-up may have been too short to reach
comparable eﬃcacy rates.23 In addition, we assessed
cyst response in terms of proportional diameter reduc-
tion as cyst volume measurements could not be
retrieved (or calculated accurately) from our medical
reports. Compared to cyst diameter reduction, volume
reduction automatically results in higher proportional
reduction rates because of mathematical diﬀerences.
In line with cyst reduction, our clinical response
rates were relatively small. One cohort of 57 patients24
reported symptom reduction in 95% of patients;
another study of 25 patients20 found reduction of symp-
toms in 72%. Both studies described high cyst reduc-
tion rates. Possibly, these high levels of symptom relief
could be explained by the stronger cyst reduction rates.
Indeed, in this study the amount of cyst reduction was
associated with clinical response. Second, our study
included a relatively high number of patients with
PLD (77%). This may have reduced our overall clinical
response rate as PLD was associated with restricted
Table 2. Adverse events.
Center 1
(n¼ 71)
Center 2
(n¼ 66) p valuea
Post-procedural pain, n/N 5/71 (7.0%) 0/66 0.06
Cyst hemorrhage, n/N 5/71 (7.0%) 1/66 (1.5%) 0.21
Cyst infection, n/N 1/71 (1.4%) 2/66 (3.0%) 0.61
Total, n/N 11/71 (15.4%) 3/66 (4.5%) 0.047
aFisher’s exact test.
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symptomatic relief (88% in solitary cysts versus 52% in
PLD patients). Indeed, in the aforementioned series the
number of PLD patients was lower (33% and 56%,
respectively).20,24
Ethanol is the most common sclerosing agent
reported in the literature as it is cheap, safe and
widely available. On the downside, ethanol sclerother-
apy has side eﬀects; mainly pain and intoxications are
described.13 Polidocanol was introduced as sclerosing
agent for hepatic cysts aiming to reduce peri- and
post-procedural pain. Indeed, in our ethanol sample,
pain was reported more frequently. Interestingly,
ethanol intoxications were not encountered, which
may be explained by the restricted maximal volume
of 50ml and relatively short sclerotherapy duration of
10 minutes.
How do our ﬁndings aﬀect clinical practice? First,
although our treatment protocols included diﬀerent
variables, we found comparable cyst reduction and
clinical response rates. This implies that the currently
available approaches probably have similar eﬃcacy
that results from cyst wall destruction leading to regres-
sion of the cyst and thereby reduction of symptoms.
As eﬃcacy rates between ethanol and polidocanol are
highly comparable, we could argue that polidocanol
should be preferred as a sclerosing agent as adverse
event rates were smaller. To draw deﬁnite conclusions,
a prospective comparison between these agents is
needed. In addition, we found that PLD patients had
less chance to gain symptomatic relief. Several studies
reported comparable ﬁndings.20,24 This conﬁned clin-
ical response may be explained by the remaining large
liver volume. In contrast, patients with solitary cysts
proved to be excellent candidates for this intervention.
The main strength of this study is the large number
of patients included from two tertiary centers. This
large sample size allowed us to correct for known con-
founders. Our study was limited by several factors.
First, median follow-up time in Center 1 was short.
Transitory reaccumulation of the treated cyst in this
period may have blurred our results and reduced
eﬃcacy of ethanol sclerotherapy. We have adjusted
for follow-up time in our regression analysis.
Nevertheless, longer follow-up periods are necessary
to provide possible long-term eﬃcacy diﬀerences.
Second, although we included confounding variables
in the regression analysis, some factors (e.g. needle
size, amount of sclerosing agent, sclerosing time, pos-
itional change) were collinear with each center and
could therefore not be included. Although these factors
may have aﬀected our outcome, the individual eﬀect of
each variable could not be evaluated. Third, exclusion
of patients for lack of imaging or suﬃcient documen-
tation may have led to selection bias. Possibly, patients
with a strong or minimal clinical response may have
been excluded (loss to follow-up or early re-interven-
tion, respectively), which may have aﬀected our eﬃcacy
rates. Finally, our clinical response and safety measure-
ments were not assessed by standardized instruments
and therefore susceptible to bias. Recently, a disease-
speciﬁc questionnaire has been validated to assess
severity and frequency of symptoms in patients with
hepatic cysts.25 This instrument opens the door for a
prospective observational study to observe long-term
clinical eﬃcacy rates. Hepatic cysts are benign lesions;
therefore, we strongly recommend using such patient-
reported outcome measures as primary endpoints to
evaluate eﬃcacy of aspiration sclerotherapy.
To conclude, despite two distinct sclerotherapy
protocols, we found comparable eﬃcacy rates of cyst
reduction and clinical relief. Polidocanol sclerotherapy
had fewer adverse events than ethanol sclerotherapy.
Future prospective studies are needed that primarily
focus on clinical relief and safety using validated
instruments.
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